Chrysarobin

For research use only. Not for therapeutic Use.

  • CAT Number: I024627
  • CAS Number: 491-59-8
  • Molecular Formula: C15H12O3
  • Molecular Weight: 240.26
  • Purity: 98%
Inquiry Now

Chrysarobin (Cat No.: I024627) is a naturally occurring anthrone compound derived from the araroba tree, traditionally used in dermatology for its antiproliferative and anti-inflammatory properties. It has been employed in the treatment of skin disorders such as psoriasis, eczema, and ringworm. Chrysarobin works by inhibiting keratinocyte proliferation and reducing inflammation. Though effective, its clinical use is limited by potential skin irritation and staining. It remains of interest in dermatological research for developing novel therapies targeting hyperproliferative and inflammatory skin conditions.


CAS Number 491-59-8
Synonyms

Chrysarobin; CCRIS5597; CCRIS-5597; CCRIS 5597

Molecular Formula C15H12O3
Purity 98%
Solubility Soluble in DMSO
Appearance Solid powder
Storage Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
IUPAC Name 3-methylanthracene-1,8,9-triol
InChI InChI=1S/C15H12O3/c1-8-5-10-7-9-3-2-4-11(16)13(9)15(18)14(10)12(17)6-8/h2-7,16-18H,1H3
InChIKey JBGKVNQFVAJOGC-UHFFFAOYSA-N
SMILES Cc(cc1O)cc2c1c(O)c(c(O)ccc3)c3c2
Reference

1: BOYMOND P, JADASSOHN W. A propos de la chrysarobine [About chrysarobin]. Dermatologica. 1947;94(4):228-30. French. PMID: 18898893.
2: Kruszewski FH, DiGiovanni J. Alterations in epidermal polyamine levels and DNA synthesis following topical treatment with chrysarobin in SENCAR mice. Cancer Res. 1988 Nov 15;48(22):6390-5. PMID: 3180057.
3: Kruszewski FH, Conti CJ, DiGiovanni J. Characterization of skin tumor promotion and progression by chrysarobin in SENCAR mice. Cancer Res. 1987 Jul 15;47(14):3783-90. PMID: 3109733.
4: DiGiovanni J, Decina PC, Prichett WP, Cantor J, Aalfs KK, Coombs MM. Mechanism of mouse skin tumor promotion by chrysarobin. Cancer Res. 1985 Jun;45(6):2584-9. PMID: 3986797.
5: Battalora MS, Conti CJ, Aldaz CM, Slaga TJ, Johnston DA, DiGiovanni J. Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Carcinogenesis. 1996 May;17(5):955-60. doi: 10.1093/carcin/17.5.955. PMID: 8640943.
6: Battalora MS, Kruszewski FH, DiGiovanni J. Inhibition of chrysarobin skin tumor promotion in SENCAR mice by antioxidants. Carcinogenesis. 1993 Dec;14(12):2507-12. doi: 10.1093/carcin/14.12.2507. PMID: 8269619.
7: DiGiovanni J, Kruszewski FH, Chenicek KJ. Modulation of chrysarobin skin tumor promotion. Carcinogenesis. 1988 Aug;9(8):1445-50. doi: 10.1093/carcin/9.8.1445. PMID: 3135955.
8: NANASI P, KOCSIS A. Beitrag zum Wirkungsmechanismus des Chrysarobins [Pharmacology of chrysarobin]. Dermatol Wochenschr. 1951;124(41):1001-3. Undetermined Language. PMID: 14905945.
9: O’Brien TG, O’Donnell K, Kruszewski FH, DiGiovanni J. Presence of a functionally altered ornithine decarboxylase activity in chrysarobin-promoted mouse epidermal papillomas. Carcinogenesis. 1988 Nov;9(11):2081-5. doi: 10.1093/carcin/9.11.2081. PMID: 3141077.
10: Sehgal VN, Verma P, Khurana A. Anthralin/dithranol in dermatology. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10. PMID: 25208745.

Request a Quote